Home  |  Contact

Cellosaurus SK-N-BE(2) (CVCL_0528)

[Text version]

Cell line name SK-N-BE(2)
Synonyms SK-N-BE2; SK-N-BE-2; SKNBE(2); SKNBE-2; SKNBE2; SK-N-BE; SKNBE
Accession CVCL_0528
Resource Identification Initiative To cite this cell line use: SK-N-BE(2) (RRID:CVCL_0528)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
From: Memorial Sloan Kettering Cancer Center; New York; USA.
Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-530.
Characteristics: Substrate-adherent type (S-type) (PubMed=15720811).
Doubling time: ~36 hours (DSMZ); 27 hours (COG).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: Deep tyrosine phosphoproteome analysis.
Omics: DNA methylation analysis.
Omics: Metabolome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations Homozygous for TP53 p.Cys135Phe (c.404G>T) (PubMed=11507071; CCLE).
Genome ancestry Source: PubMed=30894373

Origin% genome
African1.71
Native American0.88
East Asian, North1.41
East Asian, South0
South Asian7.87
European, North24.66
European, South63.46
Disease Neuroblastoma (NCIt: C3270)
Derived from metastatic site: Bone marrow.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_0529 (SK-N-BE(2)-C)CVCL_0167 (SK-N-BE(2)-M17)
Originate from same individual CVCL_9898 ! SK-N-BE(1)
Sex of cell Male
Age at sampling 1Y10M
Category Cancer cell line
STR profile Source(s): ATCC; CCRID; COG; DSMZ; PubMed=25877200

Markers:
AmelogeninX (DSMZ)
X,Y (ATCC; CCRID; COG; PubMed=25877200)
CSF1PO10
D2S133817,23
D3S135819
D5S81812
D7S8209,10
D8S117913,14
D13S31711
D16S5399,11
D18S5114,16 (CCRID; PubMed=25877200)
16 (COG)
D19S43312,13
D21S1130,31,32.2 (CCRID; PubMed=25877200)
30,32.2 (COG)
FGA22,25
Penta D13,14
Penta E14,18
TH016 (DSMZ)
6,7 (ATCC; CCRID; COG; PubMed=25877200)
TPOX8,11
vWA18

Run an STR similarity search on this cell line
Web pages http://www.cogcell.org/dl/NB_Data_Sheets/SK-N-BE2_Cell_Line_Data_Sheet_COGcell_org.pdf
http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/s/cell-lines-detail-565.html
https://www.mskcc.org/research-advantage/support/technology/tangible-material/sk-n-be-2-human-neuroblastoma-cell-line
http://www.cellresource.cn/fdetail.aspx?id=1707
Publications

DOI=10.1007/978-1-4757-1647-4_13
Biedler J.L.
Chromosome abnormalities in human tumor cells in culture.
(In) Human tumor cells in vitro; Fogh J. (eds.); pp.359-394; Springer; New York (1975)

PubMed=62055; DOI=10.1093/jnci/57.3.683
Biedler J.L., Spengler B.A.
A novel chromosome abnormality in human neuroblastoma and antifolate-resistant Chinese hamster cell lives in culture.
J. Natl. Cancer Inst. 57:683-695(1976)

PubMed=29704
Biedler J.L., Roffler-Tarlov S., Schachner M., Freedman L.S.
Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones.
Cancer Res. 38:3751-3757(1978)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=2535691
Ciccarone V., Spengler B.A., Meyers M.B., Biedler J.L., Ross R.A.
Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages.
Cancer Res. 49:219-225(1989)

DOI=10.1016/B978-0-12-333530-2.50006-X
Israel M.A., Thiele C.J.
Tumor cell lines of the peripheral nervous system.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994)

PubMed=7838528
Cheng N.C., Van Roy N., Chan A., Beitsma M., Westerveld A., Speleman F., Versteeg R.
Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification.
Oncogene 10:291-297(1995)

DOI=10.1007/0-306-46872-7_2
Thiele C.J.
Neuroblastoma.
(In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999)

PubMed=11507071
Keshelava N., Zuo J.J., Chen P., Waidyaratne S.N., Luna M.C., Gomer C.J., Triche T.J., Reynolds C.P.
Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
Cancer Res. 61:6185-6193(2001)

PubMed=11550280; DOI=10.1002/gcc.1174
Van Roy N., Van Limbergen H., Vandesompele J., Van Gele M., Poppe B., Salwen H.R., Laureys G., Manoel N., De Paepe A., Speleman F.
Combined M-FISH and CGH analysis allows comprehensive description of genetic alterations in neuroblastoma cell lines.
Genes Chromosomes Cancer 32:126-135(2001)

PubMed=15720811; DOI=10.1593/neo.04310
Walton J.D., Kattan D.R., Thomas S.K., Spengler B.A., Guo H.-F., Biedler J.L., Cheung N.-K.V., Ross R.A.
Characteristics of stem cells from human neuroblastoma cell lines and in tumors.
Neoplasia 6:838-845(2004)

PubMed=16822308; DOI=10.1186/1471-2407-6-177
Dam V., Morgan B.T., Mazanek P., Hogarty M.D.
Mutations in PIK3CA are infrequent in neuroblastoma.
BMC Cancer 6:177-177(2006)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20631050; DOI=10.1101/gr.106252.110
Storlazzi C.T., Lonoce A., Guastadisegni M.C., Trombetta D., D'Addabbo P., Daniele G., L'Abbate A., Macchia G., Surace C., Kok K., Ullmann R., Purgato S., Palumbo O., Carella M., Ambros P.F., Rocchi M.
Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure.
Genome Res. 20:1198-1206(2010)

PubMed=22213050; DOI=10.1002/ijc.27415
Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J., Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.
PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.
Int. J. Cancer 131:1556-1568(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=24792489; DOI=10.1007/s11060-014-1456-8
Farooqi A.S., Dagg R.A., Choi L.M.R., Shay J.W., Reynolds C.P., Lau L.M.S.
Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.
J. Neurooncol. 119:17-26(2014)

PubMed=25884760; DOI=10.1371/journal.pcbi.1004130
Palacios-Moreno J., Foltz L., Guo A., Stokes M.P., Kuehn E.D., George L., Comb M., Grimes M.L.
Neuroblastoma tyrosine kinase signaling networks involve FYN and LYN in endosomes and lipid rafts.
PLoS Comput. Biol. 11:E1004130-E1004130(2015)

PubMed=28350380; DOI=10.1038/sdata.2017.33
Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L., Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.
Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.
Sci. Data 4:170033-170033(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

Cross-references
Cell line collections ATCC; CRL-2271
BCRJ; 0381
DSMZ; ACC-632
ECACC; 95011815
ICLC; HTL96015
KCB; KCB 201199YJ
Cell line databases/resources CLDB; cl4332
CLDB; cl4333
CCLE; SKNBE2_AUTONOMIC_GANGLIA
CCRID; 3131C0001000700200
Cell_Model_Passport; SIDM00894
DepMap; ACH-000312
LINCS_LDP; LCL-1980
Ontologies BTO; BTO:0002696
CLO; CLO_0009052
MCCL; MCC:0000505
Biological sample resources BioSample; SAMN03472880
BioSample; SAMN03473451
BioSample; SAMN10988136
Chemistry resources PharmacoDB; SKNBE(2)_1405_2019
Gene expression databases ArrayExpress; E-MTAB-2770
GEO; GSM554389
GEO; GSM563358
GEO; GSM692869
GEO; GSM827352
GEO; GSM887593
GEO; GSM888676
GEO; GSM1366411
GEO; GSM1670450
GEO; GSM2371255
GEO; GSM2394375
Metabolomic databases MetaboLights; MTBLS104
Other Wikidata; Q54954442
Polymorphism and mutation databases Cosmic; 1019928
Cosmic; 2485941
IARC_TP53; 30154
LiGeA; CCLE_929
Entry history
Entry creation04-Apr-2012
Last entry updated06-Sep-2019
Version number27